G

Gilead Sciences

Makes medicines for HIV, liver disease and cancer

Senior Vice President - Chief Ethics & Compliance Office

Full-Time
No salary listed
Expert
JD
Foster City, CA, USA
In PersonOn-site work is required in Foster City, California.
Risk & ComplianceRegulatory Compliance & Ethics
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • At least 15 years of relevant compliance and industry experience.
  • At least 15 years of experience supporting large, global pharmaceutical companies at scale within ethical and compliance boundaries.
  • A proven track record of identifying, raising, and resolving challenging compliance and ethics issues.
  • International experience and deep understanding of global ethics, compliance, and regulatory differences across the United States, China, Europe, and Japan.
  • Experience with a broad range of therapeutic areas, ideally including virology, oncology, and inflammation, and experience bringing new products to market in a global environment.
  • Demonstrated experience building best-in-class ethics and compliance programs, establishing ethics and compliance guidelines and standard operating procedures, and supporting enterprise or multi-business-unit decision-making.
  • Experience leveraging innovation, artificial intelligence-enabled tools, automation, and data-driven insights to improve compliance effectiveness, risk detection and monitoring, process efficiency, and organizational impact.
  • Experience engaging boards of directors and senior management teams and building trusted partnerships across internal and external constituencies.
  • Experience building consensus while mitigating risk and partnering with Public Affairs, Human Resources, patient advocacy groups, and community groups.
  • Legal and compliance experience with the Commercial organization of a global pharmaceutical company.
  • Active membership in a Bar Association or equivalent body.
Responsibilities
  • Develop, evolve, administer, and direct Gilead’s global ethics and compliance strategy and programs in partnership with the Gilead Leadership Team and senior management.
  • Serve as a strategic advisor to the Gilead Leadership Team on the Global Compliance Program and articulate the value of ethics and compliance in supporting sustainable growth, patient trust, and corporate reputation.
  • Drive the evolution of the Compliance function through artificial intelligence, digital platforms, predictive analytics, technology, and automation.
  • Assess and strengthen the Compliance organization’s operating model, governance, talent capabilities, and succession planning.
  • Lead enterprise-wide compliance risk assessment, monitoring, testing, auditing, reporting, escalation, and remediation activities.
  • Monitor industry and enforcement developments and recommend policy, governance, or procedure modifications when necessary.
  • Provide leadership, escalation, and reporting on compliance matters to the Chief Executive Officer, General Counsel, Gilead Leadership Team, Board of Managers’ Audit, Compliance and Quality Committee, and Compliance Committee.
  • Develop, revise, and update policies covering healthcare, data privacy, transparency, anticorruption and anti-bribery, anti-fraud, global industry codes, and regulatory guidance for biopharmaceutical companies.
  • Create or approve compliance training content and ensure global compliance training requirements are communicated to and implemented by all employees.
  • Oversee testing and follow-up on matters reported through the company Helpline.
  • Identify compliance vulnerabilities and risks, opportunities for enhanced training, and implement corrective action plans.
  • Build and develop a world-class compliance organization and foster a high-performing, inclusive culture through mentorship, guidance, and professional development.
Desired Qualifications
  • Juris Doctor or equivalent international degree.
  • Experience managing other large corporate functions.
  • Therapeutic-area experience in virology, oncology, and inflammation.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
  • Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
  • Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

  • Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
  • Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
  • Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

  • Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
  • Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
  • Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Hip-Hop Wired
Oct 8th, 2026
Raheem DeVaughn on R&B and Black mental health.

Raheem DeVaughn on R&B and Black mental health. Published on October 8, 2026 Raheem DeVaughn talks ownership, R&B, and healing on The Morning Hustle. R&B mainstay Raheem DeVaughn stopped by The Morning Hustle for a conversation that spanned business, music, and community. The DMV favorite opened up about his new project, Quiet Storm Lover Tome Un, and his decision to re-record his 20th-anniversary album, The Love Experience. For DeVaughn, the move is about ownership. Re-recording old work creates a new master, and he wants to lead by example for independent and legacy artists chasing control of their catalogs. He also shared his love for where R&B stands today, praising fresh work from Erykah Badu and Jill Scott. DeVaughn makes music with intention, refusing to chase trends for quick money. "Music is only old to someone who hasn't heard it yet," he said, describing his focus on timeless songs that keep fans dancing for hours at deep-catalog shows. Beyond the mic, DeVaughn stays active in the community. Through his Love Life Foundation and a partnership with Gilead Sciences on the "Care for the Culture" initiative, he urges people to get tested and know their status. He also spoke candidly about mental health, encouraging Black men to seek therapy. Losing his father, he shared, pushed him into the work that revealed his own strength. Looking ahead, DeVaughn teased a City Winery tour bringing his classics to life live for fans. Stories from our partners. OkayAfrica

Boston Cambridge Biotech Networks
Sep 24th, 2026
STAT+: Why Gilead can't stop talking about its ambitions in immunology.

STAT+: Why Gilead can't stop talking about its ambitions in immunology. Speaking at recent investor conferences, Gilead Sciences' top executives have been emphatically bullish about the biotech's years-long push to develop drugs for inflammatory and autoimmune diseases. "It's one of the three scientific areas that are our core focus," Gilead Chief Financial Officer Andy Dickinson told investors at the Cantor Global Healthcare Conference earlier this month. "We're the largest virology company. We've built a robust oncology business. The third leg of the stool, so to speak, is the I&I [inflammation and immunology] business that we're growing."

Yahoo Finance
Sep 15th, 2026
Gilead partners with PAHO to expand twice-yearly lenacapavir HIV prevention access across Latin America

Gilead Sciences has partnered with the Pan American Health Organization (PAHO) to expand access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean. The agreement uses PAHO's Regional Revolving Funds to create a coordinated pathway for country-led adoption of the long-acting HIV prevention treatment. The partnership addresses a critical need in the region, where new HIV infections increased by 13% between 2010 and 2024. The agreement provides access for 14 countries outside Gilead's existing voluntary licensing agreements, including Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Mexico, Panama, Paraguay, Peru, Uruguay and Venezuela. The collaboration combines PAHO's regional coordination and procurement capabilities with Gilead's access strategy to enable sustainable scale-up of HIV prevention efforts.

BioPharma Watch
Sep 15th, 2026
Frequently asked questions.

Frequently asked questions. What is lenacapavir used for? Lenacapavir is used for HIV prevention as pre-exposure prophylaxis (PrEP). Who is partnering with Gilead for this initiative? Gilead is partnering with the Pan American Health Organization (PAHO). What regions will benefit from this partnership? The partnership aims to benefit all PAHO Member States in Latin America and the Caribbean. How will access to lenacapavir be expanded? Access will be expanded through PAHO's Regional Revolving Funds.

MarketBeat
Sep 15th, 2026
Gilead Sciences sees Yeztugo powering HIV growth as oncology pipeline advances.

Gilead Sciences sees Yeztugo powering HIV growth as oncology pipeline advances. September 15, 2026 Key points. * Yeztugo is exceeding launch expectations, with Gilead forecasting at least $1 billion in sales during its first full year. The six-month HIV prevention injection is benefiting from demand among new and existing PrEP users, while more than 70% of patients returned for a second injection. * Gilead is expanding its HIV franchise beyond Biktarvy through Bixlenvo and planned weekly oral and longer-acting treatment regimens. The company raised its HIV growth outlook to 10% and expects additional PrEP options, including a weekly pill next year and a once-yearly injection targeted for 2028. * Oncology and inflammation programs are advancing, led by the potential launch of anito-cel for later-line multiple myeloma and additional antibody-drug conjugate programs. Phase II readouts for inflammation and immunology candidates are expected later this year, supporting management's view that Gilead is at an "inflection point" for growth. * MarketBeat previews the top five stocks to own by October 1st. Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an "inflection point in value." Speaking at a Morgan Stanley event, O'Day said Gilead has its most robust portfolio of his more than seven years leading the company. He highlighted a cadence of launches across HIV, oncology and inflammation, along with the company's expectation that it faces no major patent expirations until 2036. "We are in a unique position to drive value and growth," O'Day said, citing Gilead's operating model, cash flow generation and commitment to industry-leading margins. HIV prevention growth and Yeztugo launch. Chief Commercial and Corporate Affairs Officer Johanna Mercier said the launch of Yeztugo, Gilead's every-six-month HIV prevention option, has exceeded expectations. The company expects Yeztugo to generate $1 billion in its first full year on the market, according to Mercier. Mercier said the HIV pre-exposure prophylaxis, or PrEP, market is expanding at roughly 14% to 15%, supported by awareness efforts and new treatment choices. Gilead's total prevention portfolio exceeded $1 billion in quarterly sales, representing an annualized run rate of about $4 billion, she said. The company is seeing uptake among both people new to PrEP and patients switching from other prevention options. Mercier added that growth through buy-and-bill channels has been faster than anticipated, which she said could signal that clinics are preparing to treat more patients with the six-month regimen. Gilead reported that more than 70% of patients returned for their second Yeztugo injection, based on the company's longitudinal claims analysis. Mercier said Gilead is supporting persistence through specialty pharmacy and clinic outreach, digital reminders and a nurse call center program called Ready to Go. * Gilead expects to launch a weekly oral PrEP option in the first quarter of next year. * The company is targeting a once-yearly injectable version of Yeztugo for 2028. * Mercier said the weekly oral option is expected to draw mainly from Descovy and generic Truvada users, while the six-month injection has a broader potential source of demand, including new PrEP users, daily oral users and users of other long-acting products. Mercier said the Centers for Disease Control and Prevention estimates that 2.2 million people in the U.S. could be candidates for PrEP, compared with a current user base of about 550,000. She said Gilead believes the opportunity could be larger, noting that the U.S. records approximately 13 million sexually transmitted disease diagnoses annually. Discover more Financial News Space Stocks Report Dividend Screener Tool Outside the U.S., Mercier said Gilead is working with The Global Fund and the U.S. Department of State in lower- and middle-income countries, particularly in sub-Saharan Africa. In developed markets, she said reimbursement discussions can be challenging because health technology assessment systems often compare newer long-acting therapies with daily generic oral options. HIV treatment portfolio expansion. O'Day and Mercier also described Gilead's strategy to broaden its HIV treatment business beyond Biktarvy. The company recently launched Bixlenvo, a daily oral treatment intended to help Gilead participate more extensively in the treatment-switch market. Mercier said Biktarvy remains the leading global HIV treatment, with more than 50% market share and more than two-thirds of the market among treatment-naive patients. However, she said new options are needed for patients seeking to move from Biktarvy to another regimen. Bixlenvo has indications for virally suppressed patients and for patients on complex regimens, Mercier said. The latter group represents about 5% to 6% of the overall HIV patient population and may be able to reduce multi-pill regimens to one pill daily. Gilead also expects to launch a weekly oral treatment regimen combining lenacapavir and islatravir next year through its collaboration with Merck. Longer-term development includes potential every-four-month and every-six-month treatment regimens built around lenacapavir and the investigational integrase inhibitor GS-3242. Mercier said Gilead increased its HIV growth outlook during its second-quarter update to 10% from a prior 8% to 9% range. She attributed a temporary slowing in market growth during the second quarter partly to Affordable Care Act-related effects, but said the company expects the overall HIV market to return to historical growth of 2% to 3% over the next several quarters. Oncology and inflammation pipeline. In oncology, executives highlighted anito-cel, Gilead's planned cell therapy launch for fourth-line and later multiple myeloma. O'Day described the product profile as potentially "best in disease" and said Gilead is focused on enabling longer treatment-free periods for patients. The company has fully enrolled a second-line-plus multiple myeloma study, with data expected next year. Mercier said Gilead had just under 180 authorized treatment centers for anito-cel and expects to reach about 200 by its December PDUFA date. She said the company estimates the fourth-line multiple myeloma market represents a $3.5 billion opportunity. Executives also pointed to Gilead's antibody-drug conjugate work, including Trodelvy in first-line triple-negative breast cancer and the recently acquired Tubulis ADC platform, initially targeting platinum-resistant ovarian cancer. In inflammation and immunology, O'Day said Gilead expects Phase II readouts later this year for programs targeting alpha-4 beta-7 and IRAK4. The company also has a STAT6 program and acquired a BCMA T-cell engager, gamgertamig, for potential use in rare diseases where B-cell depletion may be beneficial. O'Day said Gilead remains open to external collaborations in immunology, similar to its partnerships in HIV, particularly when combinations of differentiated medicines could accelerate patient access. About Gilead Sciences (NASDAQ:GILD). Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets. Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Gilead Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list. While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power. Continue following MarketBeat